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Introduction: Epithelioid hemangioendothelioma (EHE) is a rare endothelial tumor with an intermediate grade of
malignancy. Few cases of primary vascular hemangioendothelioma have been described in the literature. Surgery is
the treatment of choice, but radiation therapy and chemotherapy should also be considered in particular cases.
Case presentation: We present the case of a 44-year-old Caucasian woman affected by EHE of the cephalic vein,
treated by complete surgical removal of the mass and postoperative local radiation therapy. At 5-year follow-up,
our patient is alive, with no signs of local or distant relapse and with no late radiation-related effects.
Conclusions: Postoperative radiotherapy may play a role in cases in which tumor margins are close or cannot be
assessed or when high-risk features are present.
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Epithelioid hemangioendothelioma (EHE) is a rare type of
endothelial tumor that demonstrates an intermediate be-
havior between benign hemangioma and malignant angio-
sarcoma. It can occur in soft tissues, bones and visceral
organs but also as a primary tumor of the blood vessel.
About half of EHE are primary vascular. Differential diag-
nosis is often difficult, but recent diagnostic tools such as
immunohistochemistry and mutation research can be use-
ful for correct characterization. Surgery is the treat-
ment of choice, but adjuvant treatment such as radiation
therapy should be considered in the case of high-risk fea-
tures or when complete removal is not feasible. Although
sometimes promising, chemotherapy and antiangioge-
netic agents do not have a well-established role. We re-
port the case of intravascular EHE occurring in the
cephalic vein of a 44-year-old woman, treated by surgery
and postoperative radiation therapy (RT).* Correspondence: mpciliberti@libero.it
U.O. Radioterapia - National Cancer Research Centre - Istituto Tumori
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A 44-year-old Caucasian woman presented with a soft,
painless, nonpulsatile, progressively enlarging mass at the
level of the antecubital fossa of the left arm. A preliminary
ultrasound (US) scan revealed an hypoechoic solid lesion
along the cephalic vein, and a subsequent magnetic reson-
ance image (MRI) of the arm confirmed a 2×1cm mass
with a hypointense T1 signal and a weakly hyperintense T2
signal along the vein, suggesting a granuloma (Figure 1).
Upon physical examination, the mass was mobile and pain-
less; our patient did not present modification of reflexes of
her left arm or signs of venous stasis. Our patient then
underwent surgical removal of the neoplasm. Histology
confirmed the diagnosis of intravenous EHE, defined as a
‘low-grade malignancy with moderate potential to recur
locally or to metastatize’. Unfortunately, surgical margins
were microscopically involved, so our patient underwent a
second surgical operation: a 2cm segment of cephalic vein
with a lozenge of skin was excised and replaced with a graft.
The definitive histopathologic report confirmed the pres-
ence of microscopic residual foci of EHE, with free surgicall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The cephalic vein is occupied by a 2×1cm mass with a
weakly hyperintense T2 signal (T2W TSI SPIR image).
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pairment of her left arm functions. A post-surgery US study
and MRI scan did not show any residual mass, while a
total-body positron emission tomography-computed tom-
ography (PET-CT) did not show any metastatic disease to
regional lymph nodes or distant sites. Our patient was then
referred to our radiation oncology unit. In consideration of
the presence of microscopic disease foci in the second oper-
ation specimen and the considerable potential of local re-
lapse highlighted by the pathologist, our patient underwent
RT 4 months after the last surgery. A total dose of 54Gy in
27 fractions was administered with a single 6×6cm field. An
8MeV electron beam was used. Only a mild acute erythema
of the irradiated skin was recorded as acute toxicity. During
follow-up, our patient underwent MRI or ultrasound scans
of the left arm every 6 months and computed tomography
(CT) of the thorax and hepatic ultrasound scans every year.
Five years after completion of the RT, our patient is alive
with no evidence of recurrent or metastatic disease. She
presented a Radiation Therapy Oncology Group (RTOG)
grade 1 late toxicity in the irradiated skin (pigmentation
changes).
Discussion
Hemangioendothelioma (HE) is a vascular neoplasm that
shows intermediate biological behavior between benign
hemangiomas and highly malignant angiosarcomas. It has
the potential to metastatize or recur, although less fre-
quently than classic angiosarcoma.
In the most recent World Health Organization (WHO)
Classification [1] of soft tissue sarcoma, HE is included in
the group of vascular tumors of the soft tissues and of
the bones. Five subtypes of HE of soft tissues are con-
sidered: Kaposiform HE (included in the intermediate-
locally aggressive group), retiform HE, composite HE,pseudomyogenic HE (included in the intermediate-
rarely metastasizing group) and epithelioid HE, classi-
fied as a malignant tumor.
Pseudomyogenic (epithelioid sarcoma-like) HE was the
first subgroup introduced in this classification. It usually oc-
curs in young adult men on the limbs, presenting with mul-
tiple nodules. The spindle cells are characterized by a
t(7;19) translocation [2].
Kaposiform HE is a locally aggressive neoplasm that
involves superficial or deep soft tissues of children and
teenagers; it has features common to both capillary
hemangioma and Kaposi sarcoma, with several solid
poorly circumscribed nodules composed of a mixture
of small capillaries and solid lobules of endothelial cells
arranged in a glomeruloid pattern [3]. It is often associ-
ated with consumptive coagulopathy (Kasabach-Merritt
syndrome) and lymphangiomatosis [4].
Retiform HE most often occurs in the extremities of
young adults as a slowly growing single cutaneous plaque
or subcutaneous nodule microscopically characterized by
interconnecting arborizing blood vessels arranged in a
net-like pattern and minimal cytologic atypia [5]. It has
a high frequency of local recurrence but a low meta-
static potential [6].
The term ‘composite HE’ indicates a locally aggressive
vascular neoplasm of low-grade malignancy showing vary-
ing combinations of benign, low-grade malignant, and
high-grade malignant vascular components [7].
Epithelioid hemangioendothelioma (EHE) is probably the
most aggressive histological subtype. It originates from the
endothelium and most often occurs in adults of both sexes,
but may rarely also affect children [8]. It was first described
by Weiss and Enziger [9], after a review of 14 patients, as
an intermediate entity between a benign hemangioma and
a high-grade angiosarcoma. The largest series of 137 cases
of liver EHE was reported by Makhlouf et al. [10].
Histopathological evaluation is central to the diagnosis
of this tumor. Biopsy and immunohistochemical assays
are essential to establish a clear diagnosis and to dis-
tinguish EHE from other histological types such as car-
cinoma, infectious processes, metastatic adenocarcinoma
such as renal cell carcinoma, Ewing’s sarcoma, telangi-
ectatic osteosarcoma, lymphoma or multiple myeloma
(plasmatocytoma), hemangioma, epithelioid hemangioen-
dothelioma, and angiosarcoma [11,12]. Corrin et al. first
identified the angiogenic nature of these tumors based on
the identification of Weibel-Palade bodies in a kind of
lung neoplasia previously called ‘intravascular bronchi-
oloalveolar tumor’ [13].
Microscopically, EHE produces a typical dense myxo-
chondroid or myxohyaline matrix in which endothelial
cells are embedded, arranged in short strings or nests [14].
Endothelial cells are polygonal, round or occasionally fusi-
form. Usually, mitotic activity is infrequent and nuclei
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aplastic features with a high nuclear grade, necrosis and
high mitotic activity. Due to its variable histological fea-
tures, differential diagnosis can be difficult. Immunohisto-
chemistry is a useful tool: EHE shows a typical endothelial
phenotype, characterized by positivity to CD31, CD34 and
von Willebrand factor, and occasionally to cytokeratins
[15]. Recently, some studies have proposed new markers
for vascular differentiation. For example, nuclear Fli-1, a
protein expressed in endothelial cells as well as in T cells
and megakaryocytes, was detected in 100% of cases in a
series of 13 EHE and demonstrated a better sensitivity than
CD34 and better specificity than CD31 [16]. Podoplanin, a
transmembrane mucoprotein expressed in lymphatic
endothelium, alveolar type I cells, osteoblasts and peri-
toneal mesothelial cells but not in normal vascular
endothelial cells, is a useful marker to distinguish EHE
from nonvascular tumors [17,18]. FKBP12, which inhibits
Ca2+ and calmodulin-dependent calcineurin function,
regulates B and T cell responses, and is expressed in
both low- and high-grade vascular tumors, is expressed
in well-differentiated areas of EHE [19]. An immuno-
histochemical panel [20] including FKBP12 combined
with CD34 and CD31 allows a 93% diagnostic sensitiv-
ity of hemangioendothelioma.
A recurrent translocation t(1;3)(p36.23;q25.1), resulting
in the fusion of CAMTA1 on 1p36.23 to WWTR1 on
3q25.1, has recently been identified in most EHE, even if in
different sites and grades of malignancy [21,22]; this trans-
location has not been detected in other pathologies like
epithelioid hemangioma, epithelioid angiosarcoma or pseu-
domyogenic (epithelioid sarcoma-like) HE, which often
mimic EHE and make diagnosis more difficult. Another re-
current oncogenic activation secondary to TFE3 gene rear-
rangements and common fusion with YAP1 appears to be a
distinctive subset of EHE occurring in young adults, with a
clinically indolent course but a high propensity to me-
tastasis [23]. Fluorescent in situ hybridization (FISH) or
RT-PCR analysis for these fusions may be a useful mo-
lecular diagnostic tool in challenging diagnoses.
The etiology of EHE is not well known; however, pre-
disposing factors for angiosarcoma have been suggested
to include radiation, defunctionalized arteriovenous fis-
tula, foreign bodies, carotid endarterectomy and intra-
vascular prosthesis [24].
After a review of 30 patients with epithelioid EHE,
Mentzel et al. found that, although this tumor histologically
has low malignancy potential, metastatic disease occurs in
20 to 30% of patients and that overall EHE carries a risk of
death of up to 17%; thus, the authors suggested that it
should be considered a fully malignant, rather than border-
line, vascular neoplasm [25]. Local recurrence occurs in
about 10 to 15% of osseous EHE cases [12] after a relatively
long period of latency. Half of the metastases occur inlocoregional lymph nodes or lungs [26], so periodic CT scans
of regional lymph nodes and lungs are recommended in the
follow-up. However, patients with metastases could be treated
with surgery and then survive for a long time: only 20% of
them die due to the disease after 5 years [27] because half of
all metastases are in the regional lymph nodes and could be
easily controlled with local surgical excision [28]. Prognosis of
EHE remains better than that of classic angiosarcoma,
although it often remains variable and unpredictable.
Deyrup et al. analyzed 49 patients with EHE in an
attempt to identify a method for stratifying risk of mortality.
In univariate and multivariate analysis, increasing mitotic
activity and size were significantly associated with higher
mortality, while tumor site, cytologic atypia, the presence of
necrosis and tumor spindling were not significant. The au-
thors concluded that large tumors (>3cm) with high mitotic
activity (>3 mitotic figures per 50 high power fields) had
the worst prognosis with a 5-year disease-specific survival
of 59% and an increased risk of metastases (up to 25%) [8].
Clinical presentation is variable, depending on the size
and location of the tumor. EHE is often asymptomatic,
especially when it involves visceral organs such as the
lungs or liver. Nonspecific correlated symptoms can in-
clude fatigue, anorexia, nausea, or poor tolerance to ex-
ercise [29]. When a superficial vessel is involved, EHE
can present as a painful soft mass.
Radiological assessment is the first approach to identify-
ing EHE. The imaging technique used (MRI, CT, US) de-
pends on the primary site of the tumor. Increased uptake of
18-F-fluorodeoxyglucose (FDG) in this tumor has recently
been reported [30].
EHE can affect all vascularized tissues in any site, but
most frequently involves superficial or deep soft tissues,
bones [31,32] and visceral organs, in particular the liver
[33] and lungs [34,35]. Cases of EHE have been described
in almost all sites such as the skin [36,37], central nervous
system [38-40], meninges [41], lips [42], gingiva [43,44],
middle ear [45], thyroid gland [46], salivary glands [47],
paranasal sinuses [48,49], breast [50], pleura [51-53], lymph
nodes [54], mediastinum [55,56], heart [57-61], retroperito-
neum [62], ileum [63-65], peritoneum [66], testis [67], blad-
der [68,69], penis [70], vulva [71], and so on. In 10% of
cases the disease is multifocal [72].
Mortality varies depending on primary tumor site: the
mortality range is 13% for EHE of soft tissues, 31% for
EHE of the bone, 43% for EHE of the liver [10] and 65%
for EHE of the lung [14].
Primary vascular EHEs represent about 50% of reported
cases. They arise from a blood vessel [73], commonly
small- to moderate-sized veins, such as the femoral, iliac or
jugular veins, but also larger vascular structures such as the
aorta or vena cava. Few cases originate from medium- to
small-sized peripheral vessels. The intravascular subtypes
are extremely rare [74].
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soft mass in the vicinity of a peripheral vessel causing
symptoms and signs of deep venous occlusion, ranging
from edema of the extremities, weakness and ischemia,
to superior vein cava syndrome. Microscopically, they
are associated with a blood vessel, usually a medium-sized
vein [29], showing first an expansion of the affected blood
vessel and then an involvement of the surrounding soft tis-
sues, with a centrifugal proliferation pattern. It is often diffi-
cult to make a correct diagnosis in the early phase. This is
partly because they are extremely rare and also because
their imaging characteristics are nonspecific, resembling in-
flammatory or atherosclerotic lesions [24]. Ultrasonography
is useful to define the morphology and vascularization of
these masses and to evaluate blood flow, usually showing
intraluminal defects and altered flow patterns, loss of plasti-
city and velocity increase [75]. On the other hand, MRI can
give additional information about the involvement of sur-
rounding soft tissues and cleavage planes, in addition to
morphological features [27]. However, definitive radio-
logical diagnosis is often hard, and only histological diagno-
sis can be conclusive.
Forty-three case reports on primary vascular EHE of both
veins and arteries (except the aorta) have been described in
the literature (Table 1). The involved vessels were the thor-
acic aorta [76,77], aortoiliac segment [78], radial artery [27],
inferior vena cava [79-81] , superior vena cava [82-86], in-
nominate vein [55,87-91], azygos vein [92-94], femoral vein
[73,74,78,94-98], femoral artery [99] iliac veins [28,100,101],
internal carotid artery [24], axillary vein [102], brachial vein
[103] or artery [104-107], popliteal artery [108], pulmonary
artery [109], occipital artery [110], temporal artery [111],
meningeal artery [112], and digital artery [113]. Age of pres-
entation ranged from 11 to 79 years (mean age was 39
years), and the distribution among the two sexes was al-
most equal, with a slight predominance of the female sex
(59% vs. 41%). The diameter of the masses was variable,
ranging from 0.5cm to 11cm. Almost all patients under-
went surgical removal of the vascular EHE; in four cases re-
section was not complete, with macroscopic residual mass
or microscopic positive margins. After treatment, patients
were monitored for follow-up (2 to 108 months). Six pa-
tients (14%) developed distant metastases, especially liver
and lung metastases, even if this occurrence did not always
affect the overall survival when metastasectomy was per-
formed. Three patients (7%) had local relapse, often in the
cases treated by incomplete surgical removal; relapse was
always treated with a second surgery. Postoperative RT was
administered in only five cases, and chemotherapy in three
patients.
The treatment options for EHE include surgery, RT, and
chemotherapy; new therapies such as antiangiogenetics
agents have been also used. Few cases of spontaneous re-
gression of EHE have been reported [114].When feasible, surgery with free resection margins is
the treatment of choice in the management of EHE. For
example, partial hepatectomy [115] or orthotopic liver
transplantation [116] represent the first treatment in pri-
mary hepatic tumors. Embolization of feeding vessels
causing spontaneous regression of vascular tumors has
been described [117]. When feasible, a wide resection is
also recommended in primary bone EHEs. A preopera-
tive selective embolization of involved vertebra may help
to reduce intraoperative blood loss [118]. Surgery is the
mainstay also in the treatment of primary vascular EHE.
When reconstruction of the vessel is necessary, it can be
done with prosthetic or autogenous interposition graft
replacement [100]. A complete local excision of the neo-
formation with or without local lymphadenectomy is re-
lated to long-term survival.
A few patients have been treated with chemotherapy,
often in the metastatic setting, but results are not always
encouraging and response of EHE to chemotherapy seems
to be low. The mainstay chemotherapeutic agents for meta-
static EHE are doxorubicin and fluorouracil. Intensive regi-
mens using combinations of vincristine, doxorubicin,
ifosfamide, etoposide and cyclophosphamide have shown
an increase in response rate, without an advantage in over-
all survival [10]. Doxorubicin in the pegylated liposomal
formulation seems to lead to better responses [119] and re-
duce the risk of cardiotoxicity [120].
Due to the endothelial origin of EHE and the good re-
sponse to therapies with interferon (IFN) alpha [121,122],
recent therapeutic approaches have focused on the use
of antiangiogenic agents [123]. Bevacizumab is a hu-
manized monoclonal antibody directed against vascular
endothelial growth factor and seems to be an effective
and well-tolerated treatment for metastatic or locally
advanced angiosarcoma and epithelioid hemangioen-
dotheliomas [124,125]. Thalidomide [126,127], lenali-
domide [128], and endostar [129] are believed to have
immunomodulatory and antiangiogenic properties; they
also seem to be useful in the systemic treatment of EHE.
Sorafenib [130] is also providing encouraging evidence of
benefit.
Selective radionuclide therapy with intra-arterial injec-
tion of Yttrium (Y)-90 microspheres [131], commonly
used for unresectable liver metastases and primary liver
tumors with hopeful results, has shown some results in
unresectable hepatic EHE.
In consideration of the high incidence of local relapse
and the moderate radiosensitivity of EHE, RT has been
used as adjuvant treatment in some high-risk cases, with
good results. Hemangiomas involving the skeletal system
have been treated effectively with local RT for many de-
cades with a good long-term local control [132], even
when RT is used as the only treatment option, such as
in cases of surgically inaccessible sites [133].
Table 1 Cases of vascular epithelioid hemangioendothelioma described in literature










Wu et al. [109] 2014 1 F 58 Right pulmonary
artery
/ S 0 No NED 24
Mlynski et al. [96] 2013 1 F 22 Femoral vein / S 0 No M Liver and lung
metastases
12
Gundara et al. [79] 2013 1 M 39 IVC 4.5 S 0 No NED 48
Henton et al. [105] 2013 1 F 39 Brachial artery 5 S 0 No NED 12
Muñoz et al. [100] 2013 1 F 23 External iliac
vein
1.7 S 0 No NED 108
Muñoz et al. [100] 2013 1 M 44 External iliac
vein
2 S 0 RT M NED after liver-lung
metastasectomy
96
Li et al. [87] 2013 1 F 38 Innominate vein 4.2 S 0 CH NED 18
Osawa et al. [24] 2012 1 M 59 Internal carotid
artery
8 S 2 No LR + M Death 6 months after
surgery
6
Nutthaki et al. [107] 2012 1 F 42 Brachial artery 1.7 S 0 No / /
De Palma et al. [92] 2012 1 M 47 Azygos vein 1 S 0 No NED 12
Lahon et al. [82] 2012 1 F 29 SVC 4,5 S 0 No NED 10





2011 1 F 32 Popliteal artery 3 S 0 No / /
Henriquez et al. [80] 2011 1 M 31 IVC 7 S 2 CH RD Second surgery R0 /
Namaoui et al. [83] 2011 1 F 25 SVC 8 S 0 No NED 6
Minyi et al. [73] 2011 1 F 50 Common
femoral vein
3 S 0 No NED 12
Mansour et al. [55] 2010 1 M 35 Innominate vein 9.5 S 0 No NED 30
Deedar et al. [102] 2010 1 M 53 Axillary vein 5.8 S 0 No NED /
Zhang et al. [5] 2010 1 F 71 Brachial artery/
axillary artery
6.5 S 1 No NED /
El Demellay et al.
[111]
2009 1 F 41 Temporal artery 0.5 S 0 No NED 36
Scordi-Bello et al. [81] 2009 1 M 35 IVC 11 S 0 No NED 10
Tayeb et al. [110] 2007 1 F 29 Occipital artery / S 0 / NED 12
Aydin et al. [99] 2006 1 M 77 Femoral artery 6 S 0 No NED /
Kugai* et al. [97] 2006 1 F 69 Common
femoral vein
/ S / / / /
Castelli et al. [27] 2005 1 M 26 Radial artery 3 S 0 No / /
Ludwikoski et al. [101] 2005 1 F 11 Iliac vein / S / / M Liver metastases 18
Hampers et al. [113] 2002 1 F 36 Palmar arch 2.5 S 0 No NED 12
Isowa et al. [88] 2002 1 F 41 Innominate vein 3.4 S 0 No NED 28
Schröder et al. [98] 2001 1 F 52 Femoral vein 4 S 0 No NED 24
Charette et al. [95] 2001 1 M 23 Common
femoral vein
2 S 0 No NED 18
Ferretti et al. [84] 1998 1 M 79 SVC 3.5 S 2 / / Biopsy only /
Reix et al. [74] 1998 1 F 16 Common
femoral vein
2 S 0 No NED 12
Moreno et al. [89] 1998 1 M 33 Innominate vein 6 S 0 RT NED Hystiocytoid
hemangioma
7
Akashi et al. [104] 1997 1 F 67 Brachial artery 2 S 0 No NED 40
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Table 1 Cases of vascular epithelioid hemangioendothelioma described in literature (Continued)





1990 1 M 62 Innominate vein / S 0 RT NED 54
Delin et al. [78] 1990 1 F 28 Common
femoral vein
/ S 0 No NED 6
Lamovec et al. [93] 1990 1 F 40 Azygos vein
and SVC
5 S 0 RT + CH NED /
Nataf et al. [91] 1989 1 M 48 Azygos vein 2 S 2 No RD Palliative S (bypass) for
the presence of spinal
and lymph node invasion
at diagnosis
/
Harris et al. [28] 1989 1 M 32 External iliac
vein
2,5 S 0 RT NED 12
De Verbizier et al. [86] 1987 1 F 57 SVC / none / No PD Surgery only on liver
localization
6
Yousem et al. [85] 1987 1 F 35 SVC 10.5 S 0 No NED 2
Enzinger** et al. [9] 1982 1 / 11 External iliac
vein
/ S / / M 18
*Only abstract available in English language; **not available online, abstract information only. /, not specified; M, male, F, female, IVC, inferior vena cava;
SVC, superior vena cava; S, surgery; RT, radiotherapy; CH, chemotherapy; NED, no evident disease; LR, local relapse; M, metastases; R, residual tumor after surgery:
0 = no residual disease, 1 = microscopic residual cells, 2 = macroscopic residual mass; PD, progressive disease; RD, residual disease; LR, local relapse.
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EHE with adjuvant or exclusive RT. The median dose
administered was 54Gy for the patients treated with RT
alone and 62.2Gy for the patients who underwent sur-
gery, with a once daily (1.5 to 2Gy) or twice daily frac-
tionation (1.2Gy). At a median follow up of 10.3 years,
the 5-year local control, cause-specific survival, and
overall survival rates were 100%, 86%, and 79%, respect-
ively. No cases of late toxicity greater than G1 were
recorded, suggesting that RT is a highly effective treat-
ment option for this disease. Yin et al. [135] described a
case of complete remission of a cervical spine EHE after
the sole administration of 55Gy in 32 fractions over 43
days, using a 6MV photon three-field plan. No severe
side effects were recorded, but the authors highlighted
the risk of second malignancies. RT was also effective in
obtaining a long-term local control when it was adminis-
tered as adjuvant treatment [136], as in cases when
complete surgical removal was not feasible [137,138].
No direct comparisons between surgery and radiother-
apy have been published; however, high-dose radiothe-
rapy seems to be curative when used as primary or
adjuvant treatment in EHE of the spine [139,140]. Al-
though re-resection is the treatment of choice in cases
of EHE after surgery, RT showed efficacy also when
administered as salvage therapy, as in the case of EHE of
the mastoid described by Drazin et al.; the total dose ad-
ministered at recurrence was 59.4Gy in 33 fractions. The
patient was free from disease 8 years after surgery [48].
The role of RT in primary vascular EHE has not been
established. Few data are available, and it is difficult tosummarize guidelines about when this treatment should
be performed, that is preoperatively, postoperatively, in
the case of incomplete resection, or only at the moment
of tumor progression. Hampers and Tomaino described
the case of a patient with an EHE that presented as an
aneurysm of the superficial palmar arch and third com-
mon digital artery [113]. The lesion was completely sur-
gically removed and the patient received postoperative
local irradiation to the hand because surgeons and patholo-
gists could not verify tumor-free margins; dose and fraction
size were not specified. The patient was free from local or
distant recurrence at the 1-year follow-up evaluation.
Muñoz et al. described a case of external iliac vein EHE
with lymph node metastases treated by surgery and local
RT [100]. Unfortunately, doses and volumes were not spe-
cified in the report. The patient was alive without local re-
lapse at 8-year follow-up. Toursarkissian et al. described a
case of EHE arising from the innominate vein treated with
surgery and radiation therapy. The patient was alive at a
4.5-year follow-up without evidence of local relapse [90]. In
the experience of Harris et al., an EHE of the external iliac
vein with lymph-node involvement in a 32-year-old man
was treated with surgery and adjuvant radiotherapy, be-
cause microscopic foci of the tumor were seen extending to
the margins of the resection. The total dose administered
was 66Gy, and the patient was free from relapse after 12
months [28].
Conclusions
Primary vascular EHEs are rare and publications in the
worldwide literature are almost exclusively case reports.
Ciliberti et al. Journal of Medical Case Reports  (2015) 9:91 Page 7 of 10Primary vascular EHEs can occur in every age group.
Surgery is the preferred treatment, when feasible. Chemo-
therapy is often used in cases of metastatic disease, with
ambiguous results. The case reported here suggests that
the addition of postoperative RT may be useful in cases
where tumor margins are close or cannot be assessed, or
those with high-risk features. Unfortunately, EHE behav-
ior often remains unpredictable and unrelated to micro-
scopic findings.
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